The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators
Vera Therapeutics, Inc. (VERA), a late clinical-stage biotechnology company focused on serious immunologic diseases, announced Thursday positive 72-week data from the open label extension or OLE period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy or IgAN.
Vera Therapeutics (VERA) Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.